AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|
27.9 C
New York
Thursday, June 25, 2026

Tag: therapies

newssourceFORcompanyinformationcontent1marketreleases

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.

Encompass Health announces plans to build a 40-bed inpatient rehabilitation hospital in Cleveland, Tennessee

BIRMINGHAM, Ala. and CLEVELAND, Tenn., July 18, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced plans to build a freestanding, 40-bed inpatient rehabilitation...

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of the “Ministry of SMEs and Startups”, a...

- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

 Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.

A Statement from the Global Virus Network (GVN) on the Rapidly Escalating Measles Crisis in the U.S. and Worldwide

GVN is sounding the alarm over a sharp resurgence of measles cases in the United States and globally.

RxPreferred Launches My-RxP: Cutting Costs for Brand, Specialty, GLP-1, and Fertility Medications by Up to 60%

NASHVILLE, Tenn., July 16, 2025 /PRNewswire/ -- RxPreferred, a leading transparent pharmacy benefit administrator, is proud to announce the launch of My-RxP, an innovative medication...

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers